Kumquat Biosciences
Oncology Therapeutics
$135.9Mtotal raised · 3 rounds on record
2open roles
$30Mlatest round · Venture round · Jul 2021 · 5 yr ago
2backers · EcoR1 Capital, OrbiMed
Overview
Innovating life-changing medicines for cancer patients. At Kumquat, we're on a mission to transform cancer treatment by delivering durable therapeutic benefits and a renewed sense of hope to patients.
Funding and backers
Total raised
$135.9M
3 rounds on record
Latest round
$30M
Venture round · Jul 2021 · 5 yr ago
Team
90
US Form 5500 (plan participants) · Dec 2025 · +11% in a year
Hiring now
2
+2 posted in 30 days
Backers
2
EcoR1 Capital, OrbiMed
The money's age
Long since its last round
63 months since the last round · and hiring
Momentum
27/100
hiring for its size
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 29, 2021
Partnership Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses · kumquatbiosciences.com
Jul 28, 2021
Raised a round Venture round $30M · SEC Form D
Feb 5, 2021
Raised a round Venture round $50M · SEC Form D
Jul 2, 2019
Raised a round Venture round $55.9M · SEC Form D
2018
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Jul 2021 | $30M | — | SEC Form D |
| Venture round | Feb 2021 | $50M | — | SEC Form D |
| Venture round | Jul 2019 | $55.9M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Kumquat Biosciences Inc | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Yi LiuExecutive Officer, DirectorSEC Form D
Pingda RenExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Cairn Therapeutics: Targeting the Cancer, just the cancer. Making cancer treatment simpler and safer with CT-262.
Alpheus is advancing a new therapeutic approach designed to improve outcomes while reducing treatment burden for patients and families.
Creating neoantigens by design… …to transform cancer treatments into cures. ATP IS DEVELOPING THE NEXT GENERATION OF TRANSFORMATIVE LIFE…
FUTURE HOPE FOR STAGE 4 PATIENTS The team at Lifebridge 10000 continues building its patent-pending LB10000 device, built from the ground…
KAHR Bio: Pioneering Immunotherapeutics for Advanced Cancer Treatment.
Pioneering the first oral drug for FSHD and advancing cancer treatment solutions.
Jobs
$100k – $130k per year · In office · Full-Time · 6+ years exp · Bachelor's Degree · San Diego
GCP
Life Sciences
Good Clinical Practice
Apply
$190k – $225k per year · In office · Full-Time · 5+ years exp · San Diego
GCP
Apply
Salary insights
Compensation ranges based on this company's open jobs
Median
$178k
Typical range
$130k – $225k
Open positions
2
2
Jobs
Senior
50%
Architect
50%
| Level | Jobs | Median | Typical range |
|---|---|---|---|
| Senior | 1 | $130k | $130k |
| Architect | 1 | $225k | $225k |
Highest paying role
Director, Clinical Scientist
$225k
Normalized to USD per year
Visa sponsorship
1 ▼ 67%
H-1B filings in 12 months
$128k
Median offered salary
2
Open roles in United States
Who they sponsor
Biochemists and biophysicists
1
In the register as Kumquat Biosciences, Inc., San Diego, CA
Other sponsors in the same field
Eli Lilly and Company 420 filings
Regeneron Pharmaceuticals 316 filings
AbbVie 236 filings
Bristol Myers Squibb 218 filings
See 2 open roles Alert me
US Department of Labor · latest filing Apr 30, 2026 · Visa details by country
Growth
Hiring Momentum
28/100
Slowing
Open positions
2
0 opened / 0 closed in 30 days
ATS activity
Every ~5 hours
Today
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
50% ▲
Biotech
50% ▲
People
Yi Liu
Executive Officer, Director
Pingda Ren
Executive Officer
Lynn Yang
Director
Carl Gordon
Director
Scott Platshon
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Tech stack
Technologies named in job postings at Kumquat Biosciences over the last 12 months, by layer, with the share of postings for each.
Technologies in use
2
Postings analysed
2
Stack modernity
53/100
Cloud & platforms
GCP
Practices & domains
Good Clinical Practice
Sign in to see how your skills match this stack
Sign In
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
EcoR1 CapitalVia a fund
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Bayer and Kumquat Biosciences initiate Phase I study with KRAS G12D inhibitor in patients with KRAS-mutated tumors
Berlin, Germany and San Diego, USA - Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of targeting the KRAS pathway, announced today the initiation of a Phase I clinical trial with KQB548 (BAY 3771249), an investiga
Read more
Report
Bayer and Kumquat Biosciences Enter Global Exclusive License and Collaboration in Precision Oncology
Berlin, Germany and San Diego, USA - Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced that they have entered into an exclusive global license and collaboration to develop and com
Read more
Report
Kumquat Biosciences and Takeda Enter into Strategic Collaboration and Exclusive Global License Agreement to Advance Novel Oral Immuno-Oncology Drug Candidate
Kumquat Biosciences, a leader in translating breakthrough science into first-in-class therapeutics, announced today a strategic and exclusive collaboration with Takeda to develop and commercialize a novel immuno-oncology small molecule inhibitor as a mono
Read more
Report
Kumquat Biosciences and Takeda Enter into Strategic Collaboration and Exclusive Global License Agreement to Advance Novel Oral Immuno-Oncology Drug Candidate
Read more
Report
Kumquat Biosciences divulges new SOS1/GTPase KRAS interaction inhibitors
Kumquat Biosciences Inc. has synthesized son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer.
Read more
Report
Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses
INDIANAPOLIS, IN, and SAN DIEGO, CA, July 29, 2021 - Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development an
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
San Diego
San Diego
United States
HQ
The Inspiration Behind Our Name
2 open roles 2 posted in 90 days 50% engineering $178k Avg Salary
hires for Science & Research, Biotech